PER® Chemotherapy Foundation Symposium (CFS) | Conference

Dr. Venook on Distinguishing Molecular Features in CRC

November 10th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses evolving treatment strategies for patients with colorectal cancer, with regards to molecular features such as sidedness.

Dr. Mauro on Selecting Therapies for Patients With CML

January 15th 2016

Michael J. Mauro, MD, hematologist, leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses how to best select therapies for patients with chronic myeloid leukemia.

Dr. Burtness on Emerging Immunotherapies in Head and Neck Cancer

January 12th 2016

Barbara A. Burtness, MD, professor of Medicine (Medical Oncology), clinical research program leader, Head and Neck Cancers Program, co-director, Developmental Therapeutics Research Program, Yale Cancer Center, discusses emerging immunotherapies and ongoing clinical trials in head and neck cancer.

Dr. Brose on Unique Elements of the Lenvatinib Trial

November 12th 2015

Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses the lenvatinib trial.

Dr. Lynch on Targeting EGFR Mutation Subtypes in Lung Cancer

November 12th 2015

Thomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.

Dr. Ruben Mesa on Advancements in Polycythemia Vera

November 11th 2015

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses advancements in polycythemia vera (PV).

Dr. Waxman on Advancements in Acute Promyelocytic Leukemia

November 11th 2015

Samuel Waxman, MD, Distinguished Service Professor of Medicine, Hematology and Medical Oncology, Distinguished Service Professor of Oncological Sciences, Mount Sinai Health System, discusses advancements in treating patients with acute promyelocytic leukemia.

Dr. John Marshall on the Importance of Molecular Profiling in Colorectal Cancer

November 10th 2015

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.

BRAF/MEK Combination Highly Effective in Melanoma

November 6th 2015

Adding the MEK inhibitor trametinib to the BRAF inhibitor dabrafenib significantly improves long-term outcomes while lowering certain adverse events associated with either agent alone for patients with BRAF-mutated metastatic melanoma.

Dr. Weber on Dabrafenib/Trametinib Approval for Melanoma

November 6th 2015

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program and Head of Experimental Therapeutics, NYU Langone Medical Center, discusses the significance of the FDA approval of the combination of dabrafenib and trametinib for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.

Dr. Blackwell on Emerging Therapies in TNBC

November 6th 2015

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses emerging therapies for patients with triple-negative breast cancer.

Dr. Philip on Olaratumab for Soft Tissue Sarcoma

November 6th 2015

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

Targeted Therapies Improve Outcomes in Advanced Thyroid Cancer

November 5th 2015

The kinase inhibitors sorafenib and lenvatinib have significantly altered the treatment paradigm for patients with advanced radioactive iodine-refractory differentiated thyroid cancer in both older and younger populations.

Dr. Borgen on Surgical Versus Medical Treatment of Breast Cancer

November 5th 2015

Patrick I. Borgen, MD, chair, Department of Surgery, head, Brooklyn Cancer Center, Maimonides Medical Center, compares the efficacy of surgical versus medical treatment of patients with breast cancer.

In Pursuit of Less Toxic Treatments for HPV+ Oropharyngeal Cancers

November 5th 2015

While the prognosis remains good for individuals with HPV-positive oropharyngeal cancers, the incidence of these cancers continues to rise, and researchers are currently seeking less intense treatment options that are equally effective but not as toxic for patients.

Is Neoadjuvant Chemo Justified in Ovarian Cancer?

November 5th 2015

The use of neoadjuvant chemotherapy in advanced ovarian cancer continues to increase, even though the practice has not been shown to improve survival versus primary cytoreduction.

Dr. Muggia on Current Status of Intraperitoneal Therapy for Gynecologic Cancers

November 5th 2015

Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal therapy for patients with gynecologic malignancies.

Immunotherapy Not Ready for Prime Time in Ovarian Cancer

November 5th 2015

Early promising responses seen with immune checkpoint inhibitors for patients with ovarian cancer still need to be validated in larger randomized trials before a conclusion is made regarding their true efficacy.

Dr. Wu on Efficacy of Approved Agents in Colorectal Cancer

November 4th 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

Novel Antibodies Arrive in ALL

November 4th 2015

Monoclonal antibodies are poised to revolutionize the treatment of adult patients with relapsed acute lymphoblastic leukemia, specifically blinatumomab and inotuzumab ozogamicin.